• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Efficacy and Safety of SSRIs and SNRIs for Child and Adolescent Psychiatric Disorders

Efficacy and Safety of SSRIs and SNRIs for Child and Adolescent Psychiatric Disorders

January 1, 2018
Adam Strassberg, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Locher C et al,  JAMA Psychiatry 2017;74(10):1011–1020

Since the 2004 FDA black-box warning on all antidepressants for pediatric use, controversy continues over the use of SSRIs and SNRIs in children and adolescents. Both classes of medication are still commonly used for pediatric depressive disorders, anxiety disorders, and obsessive-compulsive disorder. A recently published systematic review and meta-analysis takes another look at the evidence base for these medications.

The authors reviewed 36 randomized, double-blind, placebo-controlled trials with 6,778 participants (48.6%/51.4% boy/girl, average age ~13 years). Each study compared an SSRI or an SNRI versus placebo for children or adolescents with a diagnosis of depressive disorder (17 studies), anxiety disorder (10 studies), OCD (8 studies), or PTSD (1 study). Effect sizes were calculated as standardized mean differences, and risk ratios for adverse events were also addressed. A rule of thumb for interpreting effect sizes is that ≥ 0.8 is considered a large effect, 0.5 a medium effect, and ≤ 0.2 a small effect.

The authors found medium to small effect sizes for the disorders examined: 0.56 for anxiety disorders, 0.39 for obsessive-compulsive disorders, and 0.20 for depressive disorders. (The single study for PTSD showed no statistical effect size.) For all disorders grouped together, the SSRIs and SNRIs were more beneficial than placebo by only a small to medium effect size of 0.32. However, compared with participants receiving placebo, patients receiving an antidepressant reported a statistically significant increase in adverse effects, including headache, nausea, and suicidal thoughts and behaviors, although the clinical significance of these differences is less clear.

CCPR’s take
These results are not particularly surprising. Clinicians have long noticed that serotonergic agents work better for anxiety disorders in kids than they do for depression—in line with the higher effect sizes reported for anxiety disorders (a fairly impressive 0.56) in this study. Especially given the elevated risk for serious side effects, the small effect size of 0.20 for depression is disquieting. This is yet another reminder that we should think carefully before using SSRIs and SNRIs for depression in children.
Child Psychiatry
KEYWORDS child-psychiatry depressive_disorder research-update
Adam Strassberg, MD

Probiotics for Bipolar Disorder

More from this author
www.thecarlatreport.com
Issue Date: January 1, 2018
SUBSCRIBE NOW
Table Of Contents
Efficacy and Safety of SSRIs and SNRIs for Child and Adolescent Psychiatric Disorders
CME Post-Test - Suicide in Children and Adolescents (January/February)
Note From the Editor-in-Chief
Lithium: Practical Considerations for Children With Suicidal Thinking
Helping Clinicians Manage Teen Suicide Risk
Evidence Behind Aripiprazole for the Treatment of Tourette’s Disorder
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.